Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, Gherardi G, Ene-Iordache B, Gaspari F, Perna A, Cravedi P, Bossi A, Trevisan R, Motterlini N, Remuzzi G; BENEDICT-B Study Investigators. Ruggenenti P, et al. Among authors: bossi a. J Hypertens. 2011 Feb;29(2):207-16. doi: 10.1097/hjh.0b013e32834069bd. J Hypertens. 2011. PMID: 21243736 Clinical Trial.
Preventing microalbuminuria in type 2 diabetes.
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Ruggenenti P, et al. Among authors: bossi a. N Engl J Med. 2004 Nov 4;351(19):1941-51. doi: 10.1056/NEJMoa042167. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516697 Free article. Clinical Trial.
Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.
De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P; BENEDICT Study Group. De Cosmo S, et al. Among authors: bossi a. Diabetes. 2009 Dec;58(12):2920-9. doi: 10.2337/db09-0407. Epub 2009 Aug 31. Diabetes. 2009. PMID: 19720797 Free PMC article. Clinical Trial.
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurchiu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-Iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, Remuzzi G; DEMAND Study Investigators. Ruggenenti P, et al. Among authors: bossi a. Hypertension. 2011 Nov;58(5):776-83. doi: 10.1161/HYPERTENSIONAHA.111.174474. Epub 2011 Sep 19. Hypertension. 2011. PMID: 21931073 Clinical Trial.
Glomerular hyperfiltration and renal disease progression in type 2 diabetes.
Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Dodesini AR, Trevisan R, Bossi A, Zaletel J, Remuzzi G; GFR Study Investigators. Ruggenenti P, et al. Among authors: bossi a. Diabetes Care. 2012 Oct;35(10):2061-8. doi: 10.2337/dc11-2189. Epub 2012 Jul 6. Diabetes Care. 2012. PMID: 22773704 Free PMC article. Clinical Trial.
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.
Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, Dodesini AR, Trevisan R, Bossi A, Sampietro G, Capitoni E, Gaspari F, Rubis N, Ene-Iordache B, Remuzzi G; BENEDICT Study Investigators. Ruggenenti P, et al. Among authors: bossi a. J Am Soc Nephrol. 2012 Oct;23(10):1717-24. doi: 10.1681/ASN.2012030252. Epub 2012 Aug 30. J Am Soc Nephrol. 2012. PMID: 22935482 Free PMC article. Clinical Trial.
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics.
Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F, Jiménez Sosa A, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Trevisan R, Bossi A, Zaletel J, Remuzzi G; GFR Study Investigators. Gaspari F, et al. Among authors: bossi a. Kidney Int. 2013 Jul;84(1):164-73. doi: 10.1038/ki.2013.47. Epub 2013 Feb 27. Kidney Int. 2013. PMID: 23447062 Free article.
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.
Rurali E, Noris M, Chianca A, Donadelli R, Banterla F, Galbusera M, Gherardi G, Gastoldi S, Parvanova A, Iliev I, Bossi A, Haefliger C, Trevisan R, Remuzzi G, Ruggenenti P; BENEDICT Study Group. Rurali E, et al. Among authors: bossi a. Diabetes. 2013 Oct;62(10):3599-609. doi: 10.2337/db13-0530. Epub 2013 Jun 3. Diabetes. 2013. PMID: 23733198 Free PMC article.
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
Parvanova A, van der Meer IM, Iliev I, Perna A, Gaspari F, Trevisan R, Bossi A, Remuzzi G, Benigni A, Ruggenenti P; Daglutril in Diabetic Nephropathy Study Group. Parvanova A, et al. Among authors: bossi a. Lancet Diabetes Endocrinol. 2013 Sep;1(1):19-27. doi: 10.1016/S2213-8587(13)70029-9. Epub 2013 Jun 13. Lancet Diabetes Endocrinol. 2013. PMID: 24622263 Clinical Trial.
489 results